Most oversold healthcare stocks above $10B on Wall Street amid Middle East disruptions
Seeking Alpha News (Mon, 16-Mar 10:47 AM ET)
If You Invested $1000 In IDEXX Laboratories Stock 10 Years Ago, You Would Have This Much Today
Benzinga (Fri, 13-Mar 11:15 AM ET)
IDEXX Laboratories to Present at Two Institutional Investor Conferences
Business Wire (Thu, 12-Feb 4:15 PM ET)
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
Business Wire (Mon, 2-Feb 6:30 AM ET)
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
Business Wire (Thu, 15-Jan 7:15 AM ET)
Business Wire (Thu, 15-Jan 7:00 AM ET)
IDEXX Announces CEO Succession
Business Wire (Tue, 13-Jan 8:30 AM ET)
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
Business Wire (Fri, 9-Jan 1:30 PM ET)
IDEXX Laboratories Delivers Double-Digit Revenue and EPS Growth, Boosts Outlook for 2025
Market Chameleon (Mon, 3-Nov 6:16 AM ET)
IDEXX Laboratories Lifts 2025 Outlook as Diagnostics Drive Double-Digit Growth
Market Chameleon (Mon, 3-Nov 2:37 AM ET)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Idexx Laboratories trades on the NASDAQ stock market under the symbol IDXX.
As of March 18, 2026, IDXX stock price declined to $580.35 with 275,271 million shares trading.
IDXX has a beta of 0.91, meaning it tends to be less sensitive to market movements. IDXX has a correlation of 0.19 to the broad based SPY ETF.
IDXX has a market cap of $46.21 billion. This is considered a Large Cap stock.
Last quarter Idexx Laboratories reported $1 billion in Revenue and $3.08 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.15.
In the last 3 years, IDXX traded as high as $769.98 and as low as $356.14.
The top ETF exchange traded funds that IDXX belongs to (by Net Assets): VTI, VOO, VO, QQQ, VUG.
IDXX has outperformed the market in the last year with a return of +37.4%, while the SPY ETF gained +18.2%. However, in the most recent history, IDXX shares have underperformed the stock market with its stock returning -16.6% in the last 3 month period and -8.7% for the last 2 week period, while SPY has returned -1.0% and -2.6%, respectively.
IDXX support price is $573.46 and resistance is $600.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDXX shares will trade within this expected range on the day.